Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 5:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 186 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo to Methotrexate Clear all
Completed Not applicable Interventional Results available

Coronary Flow Reserve to Assess Cardiovascular Inflammation (CIRT-CFR)

NCT02786134
View directory record Official record
Conditions
Coronary Heart Disease, Metabolic Syndrome, Diabetes Mellitus
Interventions
PET scan, Echocardiogram
Radiation
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 4, 2026, 5:14 PM EDT
Terminated Phase 2 Interventional

A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate

NCT01679951
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, JNJ-38518168 (3 mg), JNJ-38518168 (10 mg), JNJ-38518168 (30 mg), Methotrexate
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
9
States / cities
Huntsville, Alabama • Gilbert, Arizona • Covina, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Oct 4, 2026, 5:14 PM EDT
Completed Phase 3 Interventional Results available

Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis

NCT02376790
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Etanercept, Methotrexate, Placebo to Etanercept, Placebo to Methotrexate
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
851 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
55
States / cities
Tuscaloosa, Alabama • Glendale, Arizona • Mesa, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 4, 2026, 5:14 PM EDT
Terminated Phase 3 Interventional Results available

An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate

NCT01764997
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Sarilumab, Etanercept, Methotrexate, Placebo (for sarilumab), Placebo (for etanercept), Adalimumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
776 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
30
States / cities
Birmingham, Alabama • Glendale, California • Thousand Oaks, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Oct 4, 2026, 5:14 PM EDT
Completed Phase 1 Interventional

Phase 1b Study of PLX5622 in Rheumatoid Arthritis Patients Who Are Receiving Methotrexate

NCT01329991
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
PLX5622, Placebo
Drug
Lead sponsor
Plexxikon
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
4
States / cities
Anniston, Alabama • Lansing, Michigan • Duncansville, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2012 · Synced Oct 4, 2026, 5:14 PM EDT
Completed Phase 3 Interventional

A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis Currently on Methotrexate Therapy

NCT00106522
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Methotrexate, Placebo, tocilizumab [RoActemra/Actemra]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
97
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 4, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)

NCT05279417
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
ATI-450 50 mg oral tablet BID, Placebo oral tablet, Methotrexate, ATI-450 20 mg oral tablet BID
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
11
States / cities
El Cajon, California • Encino, California • La Jolla, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 4, 2026, 5:14 PM EDT
Terminated Phase 2 Interventional

BG9924 in Combination With Methotrexate for Participants With Active Rheumatoid Arthritis

NCT00458861
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
BG9924, Placebo Comparator
Biological · Other
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Oct 4, 2026, 5:14 PM EDT
Terminated Phase 2 Interventional Results available

CD40L Antagonism in Rheumatoid Arthritis (RA)

NCT05306353
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo for VIB4920, VIB4920 with TNFi, VIB4920 without TNFi
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
San Francisco, California • Aurora, Colorado • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 4, 2026, 5:14 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis

NCT06073093
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
SAR441566, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
17
States / cities
Northridge, California • Upland, California • Jacksonville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 4, 2026, 5:14 PM EDT
Completed Phase 2 Interventional

PoC in Rheumatoid Arthritis With Methotrexate

NCT00605735
View directory record Official record
Conditions
Rheumatoid Arthritis, NOS
Interventions
BMS-582949, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Palm Desert, California • Santa Monica, California • Las Vegas, Nevada + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 4, 2026, 5:14 PM EDT
Completed Phase 2 Interventional

A Study To Evaluate The Safety And Pharmacokinetic Profile Of A P38 Inhibitor (PH-797804) In Subjects With Rheumatoid Arthritis Who Are Also Taking Methotrexate

NCT00620685
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Placebo, PH-797804
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
7
States / cities
Phoenix, Arizona • Colorado Springs, Colorado • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2018 · Synced Oct 4, 2026, 5:14 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

NCT02629159
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo for Adalimumab, Adalimumab, Placebo for Upadacitinib, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
1,629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
109
States / cities
Birmingham, Alabama • Mesa, Arizona • Peoria, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 4, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis

NCT02015520
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Clazakizumab, Placebo (Matching with Clazakizumab)
Drug
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
21
States / cities
Huntsville, Alabama • Hot Springs, Arkansas • Long Beach, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Oct 4, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Study of LX3305 in Subjects With Active Rheumatoid Arthritis on Stable Methotrexate

NCT00903383
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
LX3305 low dose, LX3305 mid dose, LX3305 high dose, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
13
States / cities
Gainesville, Florida • Orange Park, Florida • Orlando, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2011 · Synced Oct 4, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Abatacept With Methotrexate- Phase IIB

NCT00162266
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept (BMS-188667), Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
26
States / cities
Birmingham, Alabama • Huntsville, Alabama • Long Beach, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2012 · Synced Oct 4, 2026, 5:14 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00235820
View directory record Official record
Conditions
Psoriasis
Interventions
adalimumab, MTX, placebo adalimumab, placebo MTX
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Abbott Park, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 17, 2008 · Synced Oct 4, 2026, 5:14 PM EDT
Completed Phase 3 Interventional Results available

An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy

NCT00973479
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Golimumab, Placebo, methotrexate (MTX)
Drug · Other
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
592 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
9
States / cities
Daytona Beach, Florida • Miami, Florida • Palm Harbor, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2013 · Synced Oct 4, 2026, 5:14 PM EDT
Completed Phase 3 Interventional Results available

Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors

NCT00960440
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CP-690,550, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
36
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 4, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients

NCT00280917
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CF101
Drug
Lead sponsor
Can-Fite BioPharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
5
States / cities
Peoria, Arizona • Albany, New York • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 4, 2026, 5:14 PM EDT
Terminated Phase 1 Interventional Results available

Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)

NCT04809623
View directory record Official record
Conditions
Cutaneous Lupus Erythematosus
Interventions
Edecesertib, Placebo, Standard of Care
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Beverly Hills, California • Clearwater, Florida • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2024 · Synced Oct 4, 2026, 5:14 PM EDT
Terminated Phase 3 Interventional Results available

A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)

NCT01230827
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
CNTO 148 (Golimumab), Placebo, Methotrexate
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 18 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Augusta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2016 · Synced Oct 4, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus

NCT02349061
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Ustekinumab IV, Placebo Infusion, Placebo SC, Ustekinumab SC, Concomitant Medication
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
12
States / cities
Huntsville, Alabama • Beverly Hills, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Oct 4, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess Immune Response Following Zoster Vaccination to Subjects With Rheumatoid Arthritis Receiving Tofacitinib or Placebo With Background Methotrexate

NCT02147587
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tofacitinib, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
36
States / cities
Jonesboro, Arkansas • Los Angeles, California • Santa Maria, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Oct 4, 2026, 5:14 PM EDT